The Mammomat B.brilliant platform was already FDA approved for full-field digital mammography, breast biopsy and titanium contrast-enhanced mammography, according to a Sept. 30 news release from Siemens Healthineers.
Three-dimensional breast imaging, or tomosynthesis, was found to detect cancer at a higher rate than mammography in a recent study.
Read the full Siemens Healthineers’ news release here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
